Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 27881 trials
Behavioral Activation for Depression: A Randomized Controlled Trial
NCT04700774
Active, positions filled
Conditions Depression
Phase NA
Enrollment 117
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The present study is a randomized controlled trial that will evaluate two versions of behavioral activation (BA); one version which is a standard BA program and one which is a motor enhanced BA program (mBA). In both programs, the patient will receive all standard BA interventions, whereas these - in the mBA program - will be supplemented with interventions focused on noticing and manipulating posture and movement associated with action initiation. The mBA program builds upon recent evidence pointing to motor manipulations of posture and movement as having the potential to assist in action initiation and thus following through with the planned activity schedule. Previous research has shown that patient compliance with the activity schedule is causally associated with depression reduction, which will be explored as a mediator of treatment gains.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Behavioral activation — Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.

Primary Outcomes

  • Depressive symptoms (PHQ-9) (Change from pre to post (10 weeks) active treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2021-01-20
Completion: 2026-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 117 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: Behavioral activation — Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
Study Locations (1 sites)
Aarhus University - Institute of Psychology and Behavioral Sciences, Aarhus, 8000 Denmark
Eligibility Criteria
Depressed participants: Inclusion Criteria: * A principal diagnosis of major depressive disorder (MDD) according to DSM-5 of a mild to moderate severity, that is, a 4 on a 0 (no depressive symptoms) to 8 (very severe symptoms) scale according to the ADIS-5 interview. * Danish language proficiency. * Ability and willingness to give informed consent. * Be either non-medicated or stabilized \[i.e., same dosage for a minimum of 8 weeks on antidepressant and antianxiety medication\]. * Access to either a smartphone, tablet, or computer with video camera Exclusion Criteria: * Severe depression deemed to require more intense psychotherapy or medication. * Non-stabilized medication (see above). * A history of bipolar disorder. * Current or past psychosis. * Substance abuse or dependence judged to require treatment. * Suicide risk requiring immediate hospitalization. * Receiving any other current psychotherapy or counseling. Healthy participants: Will only be considered for participation if they can read and understand the Danish language and deemed able and willing to give informed consent. They will undergo diagnostic interviewing to ensure the absence of a current psychiatric diagnosis and the absence of a history of bipolar disorder or psyhosis according to the ADIS-5. They will also be excluded if they receive any psychotropic medication.
A Mindfulness-Based Stress Reduction Training Program Model
NCT07544355
Not yet recruiting
Conditions Depression, Anxiety, Stress, Well-Being,...
Phase NA
Enrollment 93
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Mindfulness-based practices are used to regulate mood, alleviate or completely eliminate symptoms that cause stress and depression, and positively influence well-being. The Mindfulness-Based Stress Reduction Program is a mindfulness approach applied to individuals with physical and psychological complaints and aims to reduce stress levels (Kral et al., 2022). The Mindfulness-Based Stress Reduction Program is a widely used meditation practice that includes individual or group practices aimed at creating awareness in individuals, such as breath awareness meditation, body scan, walking meditation, and yoga, taught by a practitioner. Each of the practices involves focusing attention on the experience of the present moment (Kral et al., 2022). However, it aims for individuals under stress to respond consciously to situations instead of automatically reacting (Gotink et al., 2016). Unlike traditional meditation, the Mindfulness-Based Stress Reduction Program is based on focused attention, the individual's clear observation of themselves and events, and breath meditation. The aim is for individuals to recognize their automatic responses to events and to transform their existing responses without judgment (Gotink et al., 2016). The main objective of this study is to determine the effect of a mindfulness-based stress reduction training program on emotion regulation and stress levels of nursing students, thereby enabling them to gain competence in this area.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: The mindfulness group-"Mindfulness-Based Stress Reduction Program" — Week 1: Introduction, defining group dynamics, establishing group rules. Week 2: What is mindfulness? The breathing exercise, autopilot, raisin eating exercise. Homework: Creating mindfulness routines (brushing teeth, walking, showering, cooking or eating). Week 3: Stress, the physiology of stress, and the relationship between mindfulness and stress. Sitting meditation. Homework: Doing sitting meditation twice a week. Week 4: The relationship between thought, emotion, and behavior, Body scan meditation. Homework: Doing body scan meditation one day, sitting meditation the next. Doing 10-finger exercises. Week 5: Coping with challenging emotions and self-compassion. Self-compassion meditation. Homework: Caring for a plant or planting a flower. One day body scan, one day self-compassion meditation. Week 6: Program evaluation and closing.
  • Behavioral: The life skills workshop group-"Lifestyle Management and Well-being Workshop" — Week 1: Introduction, defining group dynamics. Week 2: Physiological Relaxation (Progressive Relaxation Exercises) Week 3: Sleep Hygiene: Circadian Rhythm and Biological Clock, Melatonin and Light Relationship, Sleep Stages and Restorative Effect Week 4: Nutrition and Stress: The effect of nutrition on stress and anxiety will be discussed: Blood Sugar Balance and "False Anxiety" (Glycemic Index), Gut-Brain Axis and Serotonin, Caffeine and Cortisol Interaction. Week 5: Social Support and Problem Solving: Time Management and Academic Stress (Problem-Oriented Coping), Social Support and Oxytocin Effect, and Recreation and "Active Rest". Week 6: Program evaluation and closing.

Primary Outcomes

  • Participant Information Form (At the end of the training, at the end of the 6th week)
  • Mindful Attention Awareness Scale (MAAS) (At the end of the training, at the end of the 6th week)
  • Depression, Anxiety, Stress Scale (DASS-21) (At the end of the training, at the end of the 6th week)
  • WHO (Five) Well-being Index (At the end of the training, at the end of the 6th week)
  • Emotion Regulation Difficulty Scale-Short Form (At the end of the training, at the end of the 6th week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-04-20
Completion: 2027-01-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 93 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul Medeniyet University
Contact Information
Study Contact:
Rujnan Tuna, PhD
+902162803153
rujnantuna@yahoo.com
Interventions
  • Behavioral: The mindfulness group-"Mindfulness-Based Stress Reduction Program" — Week 1: Introduction, defining group dynamics, establishing group rules. Week 2: What is mindfulness? The breathing exercise, autopilot, raisin eating exercise. Homework: Creating mindfulness routines (brushing teeth, walking, showering, cooking or eating). Week 3: Stress, the physiology of stress, and the relationship between mindfulness and stress. Sitting meditation. Homework: Doing sitting meditation twice a week. Week 4: The relationship between thought, emotion, and behavior, Body scan meditation. Homework: Doing body scan meditation one day, sitting meditation the next. Doing 10-finger exercises. Week 5: Coping with challenging emotions and self-compassion. Self-compassion meditation. Homework: Caring for a plant or planting a flower. One day body scan, one day self-compassion meditation. Week 6: Program evaluation and closing.
  • Behavioral: The life skills workshop group-"Lifestyle Management and Well-being Workshop" — Week 1: Introduction, defining group dynamics. Week 2: Physiological Relaxation (Progressive Relaxation Exercises) Week 3: Sleep Hygiene: Circadian Rhythm and Biological Clock, Melatonin and Light Relationship, Sleep Stages and Restorative Effect Week 4: Nutrition and Stress: The effect of nutrition on stress and anxiety will be discussed: Blood Sugar Balance and "False Anxiety" (Glycemic Index), Gut-Brain Axis and Serotonin, Caffeine and Cortisol Interaction. Week 5: Social Support and Problem Solving: Time Management and Academic Stress (Problem-Oriented Coping), Social Support and Oxytocin Effect, and Recreation and "Active Rest". Week 6: Program evaluation and closing.
Eligibility Criteria
Inclusion Criteria: * Volunteering to participate in the study, * Being a nursing student, * Having completed the pre-test, * Not having a stress score within the normal range, * Not having received any prior training on this subject, * Not having a severe psychiatric illness (psychosis, schizophrenia, etc.) diagnosed by a physician and requiring medication. Exclusion Criteria: * Not volunteering to participate in the study, * Not being a nursing student, * Not completing the pre-test, * Having a stress score within the normal range in the pre-test results, * Not having received any prior training on this subject, * Having a psychiatric illness (psychosis, schizophrenia, etc.) diagnosed by a physician and requiring medication.
Psilocybin as a Novel Therapy for Residual Anhedonia
NCT07607938
Not yet recruiting
Conditions Anhedonia, Emotional Blunting
Phase PHASE1
Enrollment 90
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study is for adults with major depressive disorder (depression) who are currently taking an SSRI or SNRI antidepressant but continue to experience anhedonia (reduced interest or pleasure) and emotional blunting. The study will test whether a single 25 mg dose of psilocybin, compared with placebo, can improve these symptoms and improve the function of brain circuits involved in reward and motivation. Researchers will measure changes using brain imaging (fMRI) and clinical questionnaires, including the Dimensional Anhedonia Rating Scale (DARS).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Psilocybin — One-time dose of psilocybin 25 mg, oral, in capsule form.
  • Drug: Placebo — One-time dose of placebo (25 mg of inert filler), oral, in capsule form.

Primary Outcomes

  • Change in Dimensional Anhedonia Rating Scale (DARS) Score (Baseline (Week -3), End of Study (Week 8))
  • Change in Fronto-Striatal Connectivity (pgACC-NAcc FC) (Baseline (Week -3), End of Study (Week 8))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Not yet recruiting
Start Date: 2026-09
Completion: 2030-09-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Joshua Siegel, MD, PhD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Julia Diamond
646-754-4744
Julia.Diamond@nyulangone.org
Interventions
  • Drug: Psilocybin — One-time dose of psilocybin 25 mg, oral, in capsule form.
  • Drug: Placebo — One-time dose of placebo (25 mg of inert filler), oral, in capsule form.
Study Locations (1 sites)
NYU Langone Health, New York, New York 10016 United States
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 65 years * Able to provide voluntary signed and dated informed consent. * Females of childbearing potential (FOCBP) must agree to practice an effective means of birth control throughout the duration of the trial * Males who have FOCBPs as partners must agree to practice an effective means of birth control throughout the duration of the trial * State willingness to comply and be available for all study requirements, including psychological, cognitive, imaging and procedural evaluations for the duration of the study * Meet DSM-5 criteria for major depressive disorder (MDD) * Screening Dimensional Anhedonia Rating Scale (DARS) total score of \< 28.5 points * Have an identified support person * Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator. Exclusion Criteria: * Inability to speak and understand English sufficiently to complete informed consent and study procedures. * Inability to provide informed consent. * Women who are pregnant or who intend to become pregnant or nurse during the study duration. * Prior exposure to classic psychedelics (i.e., psilocybin, LSD, ayahuasca, and/or mescaline) within the past 1 year. * Current or previous psychiatric conditions that meet DSM-5 criteria for psychotic disorders (i.e., schizophrenia, schizoaffective disorder, MDD with psychosis), bipolar 1 or 2 disorder, or current diagnosis of active substance use disorder. * Have active suicidal ideation with intent, based on Columbia-Suicide Severity Rating Scale (C-SSRS assessment (severity score \> 3) at the Screening visit, confirmed by the Investigator. * Have made a medically significant suicide attempt (i.e., one that had a significant possibility of causing death or permanent harm in the absence of intervention) within the past 12 months, based on Screening C-SSRS assessment and confirmation by the Investigator. * Immediate family history (i.e., parents, full siblings, or half siblings) with known or suspected psychotic disorder. * Presence of medical conditions that may confound results of imaging study or that are contraindications to or psilocybin exposure (i.e., neurological, renal, hypertension, metabolic or cardiovascular disease or pregnancy); * Presence of contraindications to MRI scanning (implantable devices, bone hardware, various IUD). * Participants who received electroconvulsive therapy (ECT), trans magnetic cranial stimulation (TMS), and/or ketamine in the past 90 days. * Has any other physical or psychological symptom, medication, or other relevant finding prior to randomization that, based on the clinical judgment of trial personnel, would make a participant unsuitable for the trial. * Are unable or unwilling to discontinue taking any protocol-prohibited medications and supplements.
Psychological Burden of Anxiety and Depression Among Future Physicians: A Cross-sectional Study at Assiut University Faculty of Medicine
NCT07197125
Not yet recruiting
Conditions Anxiety, Depression
Phase Not Applicable
Enrollment 289
Locations 0 sites
Compensation Compensation varies
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

A cross-sectional study will be conducted to assess the prevalence of anxiety and depression among medical students and interns at Assiut University, examining associated risk factors and their correlation with academic performance.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Prevalence of anxiety among medical students at Assiut University (baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Not yet recruiting
Start Date: 2026-07-01
Completion: 2027-12-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 289 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assiut University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
N/A
Eligibility Criteria
Inclusion Criteria: * Medical students at Assiut University (1st - 5th year) Medical interns (1st and 2nd year) at Assiut University Hospital Exclusion Criteria: * Individuals with a previously diagnosed neurological disorder Individuals with a previously diagnosed psychiatric disorder
ASHA Bangladesh--An Integrated Intervention to Address Poverty and Depression
NCT06295250
Recruiting
Conditions Depression, Economic Vulnerability, Anxi...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled trial is to compare the impact of an integrated intervention combining poverty alleviation and depression treatment to depression treatment alone, in low income rural Bangladeshi women with depression. The main question\[s\] it aims to answer are whether adding poverty alleviation to depression treatment in an integrated intervention: 1) improves depression outcomes at 6 months post baseline as measured by changes in the PHQ-9 from baseline--compared to depression treatment alone; 2) reduces the chance of relapse (PHQ-9 \>=5) at 18 months among patients who remitted (PHQ-9\<5) at six months--compared to depression treatment alone; and 2) whether adding poverty alleviation to depression treatment improves implementation outcomes including treatment uptake and retention--compared to depression treatment alone. Other outcomes that will be studied include economic vulnerability and psychosocial variables such as anxiety, culturally specific symptoms, quality of life, and function. Participants in both arms will participate in research interviews at 6,12 and 18 months. The project also includes a mixed methods implementation evaluation. Quantitative implementation outcomes to be examined include adoption/uptake; retention in the intervention, and fidelity of intervention delivery. A qualitative process evaluation will include interviews with 80 study participants and approximately 40 staff members, including research staff, agricultural officers, and interventionist staff.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Manualized Group Based Psychotherapy — Participants in the control group will receive a 10-session 6-month manualized group based psychotherapy treatment. The treatment is adapted from a WHO program called Problem Management Plus (PM+). PM+ includes 4 evidence based strategies: 1) problem solving; 2) increasing social support; 3) behavioral activation; and 4) relaxation through deep breathing. The intervention is delivered by trained non professional peers.
  • Other: Poverty Alleviation — In addition to the psychotherapy intervention described above, participants in the experimental group will receive a poverty alleviation intervention adapted from the well-known Graduation Program--a poverty alleviation intervention widely used in low income countries. The poverty alleviation intervention includes a) 4 sessions of financial literacy education; b) savings accounts; c) consumption support equal to the cost of 1kg of rice per day for six months; d) productive asset transfer of 3 goats; e) 12 months of animal feed and veterinary care; f) gardening supplies; g) agricultural skill building.

Primary Outcomes

  • Change in Depressive symptoms at 6 Months (6 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2026-12
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Collaborators: International Centre for Diarrhoeal Disease Research, Bangladesh, Georgetown University, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Alison Karasz, PhD (PRINCIPAL_INVESTIGATOR) - UMass Chan Medical School
Contact Information
Study Contact:
Alison Karasz, PhD
3478435652
alison.karasz@umassmed.edu
Interventions
  • Behavioral: Manualized Group Based Psychotherapy — Participants in the control group will receive a 10-session 6-month manualized group based psychotherapy treatment. The treatment is adapted from a WHO program called Problem Management Plus (PM+). PM+ includes 4 evidence based strategies: 1) problem solving; 2) increasing social support; 3) behavioral activation; and 4) relaxation through deep breathing. The intervention is delivered by trained non professional peers.
  • Other: Poverty Alleviation — In addition to the psychotherapy intervention described above, participants in the experimental group will receive a poverty alleviation intervention adapted from the well-known Graduation Program--a poverty alleviation intervention widely used in low income countries. The poverty alleviation intervention includes a) 4 sessions of financial literacy education; b) savings accounts; c) consumption support equal to the cost of 1kg of rice per day for six months; d) productive asset transfer of 3 goats; e) 12 months of animal feed and veterinary care; f) gardening supplies; g) agricultural skill building.
Study Locations (1 sites)
International Centre for Diarrhoeal Disease Research, Dhaka, Dhaka Division Bangladesh
Eligibility Criteria
Inclusion Criteria: 1. Age 18-45 2. Meets criteria for Economic Vulnerability as measured by: household income \<= 15000 Taka per month; food insufficiency in household over previous six months; OR owning \<= 10 decimals of land 3. Family willingness to participate in the program 4. Basic literacy as measured by ability to read a simple sentence; 5. A score \>=10 on the Patient Health Questionnaire (PHQ-9 Depression Scale) at baseline Exclusion Criteria: 1. Pregnancy at screen; 2. Cognitive or physical impairment precluding participation 3. Plans to relocate or to travel for \> 1 month during 18 M period. 4. Household debt greater than 70,000 Taka
VGR Accelerated TMS Treatment for Depression
NCT06138678
Recruiting
Conditions Depression
Phase NA
Enrollment 146
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Intermittent theta burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well documented method for treatment of depression. The aim of the study is to assess the effect of an accelerated iTBS protocol compared to a routine iTBS protocol. In the accelerated protocol patients will receive 1200 pulses per session (2 sessions per day, 15 treatment days) and in the routine protocol patients will receive 600 pulses per session (1 session per day, 30 treatment days). Participants (n = 146) will be recruited among patients referred to iTBS and randomized to treatment. Participants will be assessed by a psychiatrist, or a resident psychiatrist, prior to treatment to assure that they fulfill all inclusion criteria and non of the exclusion criteria. A psychiatrist, or a resident psychiatrist, will assess depressive symptoms 3 and 6 weeks after first day of treatment. Patients will complete self-rating questionnaires during screening, weekly for 6 weeks starting from the first day of treatment, and 6 months after end of treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: iTBS (intermittent theta-burst stimulation) — The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.

Primary Outcomes

  • Difference in MADRS-S from baseline to three weeks after first iTBS treatment (3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-15
Completion: 2027-08-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 146 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Collaborators: Göteborg University, Uppsala University, The Swedish Society of Medicine
Principal Investigators:
  • Melker Hagsäter, MD, MSc, PhD (PRINCIPAL_INVESTIGATOR) - Västra Götaland Regional Council
Contact Information
Study Contact:
Melker Hagsäter, MD, MSc, PhD
+46 3039 8000
melker.hagsater@vgregion.se
Interventions
  • Device: iTBS (intermittent theta-burst stimulation) — The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Study Locations (2 sites)
Kungälv Hospital, Kungälv, Sweden
Hospital of Skövde, Skövde, Sweden
Eligibility Criteria
Inclusion Criteria: * diagnosis of depression verified through a Mini International Neuropsychiatric Interview (M.I.N.I.) * MADRS-S \>= 20 * unchanged medication last month * unchanged psychological treatment last month * admitted to psychiatric ward last month * no ECT or TMS last six months * provision of signed informed consent form * indication for TMS is depression Exclusion Criteria: * addiction (illicit drugs or alcohol) * pregnancy * epilepsy * conductive ferromagnetic or other metals implanted in the head or within 30 cm of the treatment coil * implanted device that is activated or controlled in any way by physiological signals * implanted mediation pumps * intracardiac lines, even when removed * regular use of benzodiazepines * any condition that seriously increases the risk of non-compliance or loss of follow-up
Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression
NCT05480826
Recruiting
Conditions Psychiatric Disorder
Phase NA
Enrollment 50
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Genetic analyses conducted on patient with psychiatric disorders assessed at the expert centres resulted in the identific action of genetic variants associated with psychiatric disorders (Courtois, 2020). These data require further genetic and functional analyses. The first objective of this study is to investigate the disease-related inheritance of genetic variants in the families of individuals in whom these variants have been identified. The second objective is to explore the functional consequences of disease-associated genetic variants in patients cells and those of their relatives with and without these variants. The present project aims to enrich existing biocollections with DNA from blood or saliva from relatives of patients identified with genetic variants. In addition, we wish to collect hair follicules from patients with identified genetic variants of interest and their family members who wish to participate in the study. These hair samples with SNA will be used to dedifferentiate the isolated cells into induced pluripotent stem cells (IPSCs), and then to differentiate them into cells expressing the gene of interest, such as neurons or astrocytes, or into more complex systems, such as brain organoids.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Genetic: study of the transmission of genetic variants — the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA

Primary Outcomes

  • Measure of the probability of having a psychiatric disorder given the presence of the genetic variant studied. (through study completion, an average of 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-15
Completion: 2028-09-15
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondation FondaMental
Principal Investigators:
  • Marion Leboyer, MD PhD (STUDY_CHAIR) - Fondation FondaMental
  • Stephane JAMAIN, PhD (STUDY_DIRECTOR) - Institut National de la Santé Et de la Recherche Médicale, France
Contact Information
Study Contact:
Stephane JAMAIN, PhD
149813775
stephane.jamain@inserm.fr
Interventions
  • Genetic: study of the transmission of genetic variants — the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
Study Locations (1 sites)
Hopital Albert Chenevier, Créteil, 94000 France
Eligibility Criteria
Inclusion Criteria: * For patients: * Subjects suffering from (according to DSM IV criteria) : Bipolar disorder, Unipolar depression, Schizophrenia, Autism spectrum disorder * Age over 18 years * Subject affiliated to the social security system * Including patients under guardianship, curatorship, * Patients included in the Fondation FondaMental cohort whose genetic analyses have revealed the need for comparative and functional genetic studies. * Having signed the consent form For relatives : * Age over 18 years * Relative of patient included in the Fondattion FondaMental cohort * Including relative under guardianship, curatorship * Having signed the consent * Affiliated to social security Exclusion Criteria: * For all subjects: * Any condition that, in the opinion of the investigator, would make the subject's participation in the study undesirable or that would compromise compliance with the protocol * Persons deprived of liberty * Inability to understand French
Adolescent Mood During Puberty and Testosterone
NCT06072677
Recruiting
Conditions Adolescent Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Starting at puberty, female adolescents are nearly three-times more likely to develop internalizing disorders, like depression, while male adolescents are two-times more likely to develop externalizing disorders, like attention deficit hyperactivity disorder (ADHD). This divergence between the sexes during puberty suggests sex-specific pathways of risk and differential effects of sex hormones. The purpose of this research is to determine: 1) sex-specific neural and endocrine features of the pubertal transition that may mediate sex differences in adolescent mood disorders, and 2) the neurophysiological basis of susceptibility to hormone change during puberty.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Healthy Minds Program — The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.

Primary Outcomes

  • CES-DC Score Over Time (up to Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-24
Completion: 2027-12
Eligibility
Age: 11 Years
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: Foundation of Hope, North Carolina
Principal Investigators:
  • Elizabeth Andersen, PhD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Kayla Jensen, BS
919-445-6815
nerdlab@unc.edu
Interventions
  • Behavioral: Healthy Minds Program — The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
Study Locations (1 sites)
Carolina Crossing B, Suite 1, Chapel Hill, North Carolina 27517 United States
Eligibility Criteria
Inclusion Criteria: * Between the ages of 11 and 14 * Have their own personal mobile device and capability to download the MyCap and Healthy Minds apps * Experienced a stressful life event within the last year, or endorse moderate depression (defined by a CES-DC score 16 or higher) Exclusion Criteria: * Previous experience with the Healthy Minds Program * Regular meditation practice * Current or history of manic episodes, psychotic symptoms, or current suicidal intent * Taking any form of exogenous hormones or intrauterine device (IUD) within one month of participation in the study * Taking medications that directly alter cardiovascular or neurological function
Mindfulness Engaged Neurostimulation for Depression (MEND II)
NCT07512284
Recruiting
Conditions Depression, Treatment Resistant Depressi...
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Combination Product: Medi-TBS — The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.

Primary Outcomes

  • Change in EEG source localized pDMN alpha activity (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-01
Completion: 2029-04-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Contact Information
Study Contact:
Jyoti Mishra, PhD
858-232-2855
braine@ucsd.edu
Interventions
  • Combination Product: Medi-TBS — The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
Study Locations (1 sites)
UC San Diego Health Psychiatry, San Diego, California 92037 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of major depressive episode (MDE, in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder. * At least one failed antidepressant medication trial at level 3 in the Antidepressant -Treatment History Form: Short Form (ATHF-SF) classification. * Montgomery-Åsberg Depression Rating Scale (MADRS) Score \>19 (moderate - severe depression). * No increase or initiation of new antidepressant therapy in the four weeks prior to screening. * Demonstrated capacity to give informed consent. Exclusion Criteria: * Inability to provide informed consent. * Medically unstable patients. * Concomitant neurological disorder or a history of a seizure disorder. * Exhibiting current suicidal behavior rating on the Columbia Suicide Severity Rating Scale (C-SSRS) * Patients who are pregnant or breastfeeding. * Any psychotic disorder or current active psychotic symptoms. * Patients who have intracranial implants, other medical device or condition deemed unsafe for TMS. * Contraindication to MRI scanning.
Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss
NCT07073521
Recruiting
Conditions Depression, Anxiety, Visual Impairment, ...
Phase NA
Enrollment 45
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to develop and pilot test a therapeutic strategy combining cognitive behavioral therapy (CBT) with mindfulness practices tailored for individuals adjusting to vision loss. The study will begin with focus groups to inform the design of the intervention. Participants will complete brief surveys on their background and experiences with vision loss prior to attending a focus group, and some may be invited to a second session to provide additional feedback before preliminary testing begins. In the pilot phase, participants will attend weekly group therapy sessions using the developed intervention and complete assessments before and after the program, including questions about vision status, demographics, and experiences with vision loss.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss — The intervention will be an 8-week integrated group therapy curriculum combining cognitive behavioral therapy (CBT) with mindfulness practices designed for individuals adjusting to vision loss.

Primary Outcomes

  • Change from Baseline in Mean Adaption to Vision Loss (AVL) Scale Score (Assessed at baseline and following the 8-week intervention period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-14
Completion: 2027-07-13
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Chicago Lighthouse
Principal Investigators:
  • Chief Research Officer (PRINCIPAL_INVESTIGATOR) - The Chicago Lighthouse
Contact Information
Study Contact:
Senior Research Associate
(312) 447-3254
Research@chicagolighthouse.org
Interventions
  • Behavioral: Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss — The intervention will be an 8-week integrated group therapy curriculum combining cognitive behavioral therapy (CBT) with mindfulness practices designed for individuals adjusting to vision loss.
Study Locations (1 sites)
The Chicago Lighthouse, Chicago, Illinois 60608 United States
Eligibility Criteria
Inclusion Criteria: * Adults who are at least 18 years old * Experiencing varying degrees of vision loss (e.g. mild, moderate, severe) * Willingness to participate in the focus group or pilot testing and provide feedback Exclusion Criteria: * Individuals with severe cognitive impairment affecting participation * Congenital blindness * Recent or current participation in another clinical trial study or medical intervention that may interfere with study results * Documented or self-reported health condition that may interfere with the outcomes of this study. * Deemed unfit to participate in the study by the site investigator * Unwilling and/or unable to participate or provide consent
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
NCT02434393
Recruiting
Conditions Major Depression, Late Life Depression (...
Phase Not Applicable
Enrollment 120
Locations 2 sites
Compensation Compensation varies
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison. Depression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct. (5 years (parent protocol), 5 years (continuation))
  • Rate of Change in expressive language as measured by the Boston Naming Test using total correct. (5 years (parent protocol), 5 years (continuation))
  • Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall. (5 years (parent protocol), 5 years (continuation))
  • Change in brain structure using magnetic resonance imaging (MRI) (5 years (parent protocol), 5 years (continuation))
  • Extent of amyloid deposition as measured by florbetapir (5 years (parent protocol), 5 years (continuation))
  • Extent of tau deposition as measured by flortaucipr (5 years (continuation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2015-03-04
Completion: 2027-05
Eligibility
Age: 65 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Institute of Mental Health (NIMH), University of California, San Francisco, Alzheimer's Therapeutic Research Institute
Principal Investigators:
  • Scott Mackin, PhD (STUDY_DIRECTOR) - University of California, San Francisco
Contact Information
Study Contact:
Nithya Ganesh
(415) 300-0582
nithya.ganesh@ucsf.edu
Interventions
N/A
Study Locations (2 sites)
University of California, San Francisco, San Francisco, California 94143 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: 1\. Individual participated in original Characterizing Cognitive Decline in Late Life Depression study or Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression Study. Exclusion Exceptions: 1. Antidepressant medication treatment is allowed only if the medication dose is stable for 4 weeks prior to the MRI scan. 2. Psychotherapy interventions is allowed only if they have completed at least 4 weeks of individual or group psychotherapy intervention prior to the MRI scan. 3. Participants taking cognitive enhancing medications will be able to enter the study.
Aβ Dynamics in LLMD
NCT05004987
Recruiting
Conditions Alzheimer Disease, Major Depressive Diso...
Phase PHASE4
Enrollment 60
Locations 2 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis is that a reduction in depressive symptoms will be associated with a normalization of CSF AD biomarkers as well as peripheral inflammatory markers. This research would contribute to fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Escitalopram Oxalate — The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
  • Drug: Placebo — Daily dose of placebo will mimic that of ESC.

Primary Outcomes

  • Change in Cerebrospinal Fluid (CSF) Aβ40 Biomarker Levels (Baseline, Week 8)
  • Change in Cerebrospinal Fluid (CSF) Aβ42 Biomarker Levels (Baseline, Week 8)
  • Change in Vascular Dysfunction (VD) Biomarker Levels (Baseline, Week 8)
  • Change in Scores on Montgomery-Asberg Depression Ration Scale (MADRS) (Baseline, Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-02-04
Completion: 2027-06-30
Eligibility
Age: 60 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute on Aging (NIA)
Principal Investigators:
  • Nunzio Pomara, MD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Antero Sarreal, MD
845-398-6532
Antero.sarreal@nki.rfmh.org
Chelsea Reichert Plaska, PhD
845-398-5583
Chelsea.reichert@nki.rfmh.org
Interventions
  • Drug: Escitalopram Oxalate — The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
  • Drug: Placebo — Daily dose of placebo will mimic that of ESC.
Study Locations (2 sites)
NYU Langone Health, New York, New York 10016 United States
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962 United States
Eligibility Criteria
Inclusion Criteria: 1. Male and female subjects, age 60+ years inclusive, at the time of signing the informed consent. 2. Meeting Structured Clinical Interview (SCID-5-RV) for DSM-5 criteria for Major depressive disorder. 3. Montgomery-Åsberg Depression Rating Scale (MADRS) ≥18. 4. Have results of a physical examination, neurological examination, vitals, and EKG within normal limits at screening. 5. Cognitively unimpaired at screening visit as defined by Mini-Mental State Examination (MMSE) \>27. 6. Clinical Dementia Rating Scale (CDR) Global of 0\*. 7. A score of 85 or greater on the RBANS delayed memory index score. 8. Fluent in English, because some of the instruments used in this study have not been translated and validated in other languages, and are able to read at a 6th grade level or equivalent, as determined by the PI. 9. Medically stable with no significant cerebrovascular, neurological, or systemic disease expected to interfere with the study. 10. Adequate auditory acuity and normal-to-corrected vision. 11. Willing to undergo brain MRI, urine drug screen and blood sampling for routine laboratory testing, lumbar puncture, APOE genotyping and plasma drug levels. 12. Only individuals with normal or non-clinically significant abnormalities on routine laboratory tests, will be included. * If study partner is not available, the CDR will be skipped. Exclusion Criteria: 1. History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, or confluent (or more extensive) white matter hyperintensities. 2. Mental retardation, or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders). 3. Subjects with a Fazekas scale \>2. 4. Significant history of alcoholism or drug abuse in the past 2 years. Fulfilling SCID-5-RV/DSM-5 criteria for current or past diagnosis of any psychiatric disorder (e.g., schizophrenia, bipolar disorder, or any psychotic disorder) other than recurrent MDD or anxiety disorders (e.g., panic disorder, agoraphobia, etc.). 5. A current significant risk for suicidality based on the Columbia-Suicide-Severity Rating Scale (C-SSRS). 6. Insulin dependent diabetes. 7. Evidence of clinically relevant or unstable cardiac, pulmonary, endocrine or hematological conditions. 8. Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging. 9. Positive urine drug screen for illicit drugs. 10. History of poor tolerance to, poor response to, or ongoing treatment with escitalopram. 11. If taking antidepressants, currently taking fluoxetine, due to the length of time required to washout. 12. Treatment with following medications will not be permitted. In some cases, medications will be allowed if medically prescribed and dose regimen stable. Note: Some medications (e.g., amphetamines, opiates) may appear on the routine urine drug test in the screening period but can be allowed as per protocol. * For subjects taking prescribed psychoactive medications and supplements (i.e., opioids, amphetamines, amphetamine-like substances, and cannabinoids), must be on a stable dose for 1 month prior to randomization. * Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline). * Cholinesterase inhibitors and memantine * Continuous aspirin (any dosage) use which can affect platelet function is prohibited. Exception: If participant is on low dose aspirin for prophylaxis and is willing to temporarily discontinue prior to research blood draw (i.e., 2 days before). * Continuous use of other medications which are also known to affect platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs), anti-histamines. Exception: If participant is taking medication continuously and is willing to temporarily discontinue prior to research blood draw (i.e., 2 days before)
TACS on High-inflammatory and Refractory Depression
NCT06812923
Recruiting
Conditions Treatment Resistant Depression (TRD), In...
Phase NA
Enrollment 52
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomized controlled trial with a duration of 12 weeks (4 weeks of intervention + 8 weeks of follow-up). The participants are patients with treatment-resistant depression (TRD) and high inflammatory activity (n=52). The study aims to clarify the effectiveness of 15mA, 77.5Hz transcranial alternating current stimulation (tACS) in treating TRD with high inflammatory activity by comparing the changes in depressive symptoms and biological markers after active tACS stimulation versus sham stimulation. Additionally, the study seeks to explore potential underlying mechanisms of action.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: transcranial Alternating Current Stimulation (tACS) — tACS, parameters: 15mA、77.5Hz tACS, 20 times (5 times a week, four weeks totally)
  • Device: Sham stimulation — Sham stimulation, matched with real tACS, except for providing electrical stimulation

Primary Outcomes

  • the change in scores of HAMD-17 after treatment (4 weeks (at the end week 4))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Anding Hospital
Contact Information
Study Contact:
Chenghao Yang, PhD
0086-022-88188299
yangchh@tjmhc.com
Interventions
  • Device: transcranial Alternating Current Stimulation (tACS) — tACS, parameters: 15mA、77.5Hz tACS, 20 times (5 times a week, four weeks totally)
  • Device: Sham stimulation — Sham stimulation, matched with real tACS, except for providing electrical stimulation
Study Locations (1 sites)
The 20th ward of general psychiatric department, Tianjin, Tianjin Municipality 300000 China
Eligibility Criteria
Inclusion Criteria: * (1) Aged between 18 and 55 years; (2) Diagnosed with depression through a structured clinical interview by a psychiatrist using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); (3) A total score of 17 or above on the 17-item Hamilton Depression Rating Scale (HAMD-17), with a score of 2 or more on item 1 (depression); (4) CRP level between 0.85-10 mg/L; (5) DM-TRD score of at least 12.5; (6) Stable use of treatment medications (antidepressants, antipsychotics) for at least 2 weeks during the current depressive episode; (7) Able to understand and sign the informed consent form. Exclusion Criteria: * (1) A history of current or past seizures, epilepsy, hydrocephalus, central nervous system tumors, or acute brain injury and infections; (2) A score of 3 or 4 on item 3 of the HAMD-17, or a history of suicidal behavior with significant suicide risk; (3) Received electroconvulsive therapy (ECT), modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), tACS, or other neuromodulation treatments within one month prior to enrollment; (4) Pregnant or breastfeeding women; (5) Patients with any severe organic disease or in an unstable condition due to organic disease; (6) Used anti-inflammatory drugs for more than 7 days cumulatively in the last 2 months, or used immunosuppressive drugs, such as corticosteroids; (7) Suffering from chronic infectious or autoimmune diseases, such as lupus, enteritis, hepatitis, etc.; (8) A history of substance dependence or substance abuse.
Parent Encouragement And Coaching of Happiness in Youth
NCT06725160
Recruiting
Conditions Depression, Parent-Child Relations
Phase NA
Enrollment 180
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this mechanistic clinical trial is to examine whether parent-coaching aimed at increasing child positive affect will increase child neural response to reward. The main questions it aims to answer are: Aim 1. Characterize child neural reward response and its relation to maternal socialization of positive emotions at baseline in healthy young children. Aim 2. Evaluate how coaching-related changes in maternal socialization of positive emotion expression contribute to increases in child neural reward response over time. Aim 3. Examine how maternal socialization of positive emotion expression contributes to increases in child neural reward response in the moment. Participating mother-child dyads will be randomized to either 3 sessions of parent coaching of child positive affect or 3 sessions of a general parenting support intervention and neural response to reward and affective behavior will be examined pre and post intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Parent Coaching — Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
  • Behavioral: Active Control — General parent support and psychoeducation based on components of standard PCIT.

Primary Outcomes

  • Reward Positivity (RewP) (From baseline week 1 to final assessment week 5 (week 10 maximum))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-28
Completion: 2029-02-01
Eligibility
Age: 4 Years
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Judith M Morgan, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
  • Lauren M. Bylsma, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Julie Research Coordinator
412-509-8787
PEACHY@upmc.edu
Interventions
  • Behavioral: Parent Coaching — Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
  • Behavioral: Active Control — General parent support and psychoeducation based on components of standard PCIT.
Study Locations (1 sites)
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria for Mothers: * Birth mother (biologically female, any gender) * Providing regular care for participating child (i.e., at least 50% of time) * Elevated, clinically significant levels of depression (16 or higher on CES-D) * Aged 18+ Exclusion Criteria for Mothers: * Lifetime history of a bipolar disorder * Lifetime history of a psychotic disorder Inclusion Criteria for Participating Child: -Aged 4-6 years Exclusion Criteria for Participating Child: * T-score greater than 63 on the internalizing or externalizing composites of the CBCL * Lifetime history of a psychiatric illness * Lifetime history of neurodevelopmental disorder * Lifetime history of neurological disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624
Recruiting
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 200
Locations 18 sites
Compensation Phase 3: Typically $200-$1,000
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: NBI-1065845 — NBI-1065845 tablets
  • Drug: Placebo — Matching placebo tablets

Primary Outcomes

  • Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56 (Baseline, Day 56)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-01-22
Completion: 2027-07
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neurocrine Biosciences
Principal Investigators:
  • Clinical Development Lead (STUDY_DIRECTOR) - Neurocrine Biosciences
Contact Information
Study Contact:
Neurocrine Medical Information Call Center
1-877-641-3461
medinfo@neurocrine.com
Interventions
  • Drug: NBI-1065845 — NBI-1065845 tablets
  • Drug: Placebo — Matching placebo tablets
Study Locations (18 sites)
Neurocrine Clinical Site, Little Rock, Arkansas 72204 United States
Neurocrine Clinical Site, Garden Grove, California 92844 United States
Neurocrine Clinical Site, Orange, California 92866 United States
Neurocrine Clinical Site, Pico Rivera, California 90660 United States
Neurocrine Clinical Site, San Diego, California 92103 United States
Neurocrine Clinical Site, Upland, California 91786 United States
Neurocrine Clinical Site, Hollywood, Florida 33024 United States
Neurocrine Clinical Site, Maitland, Florida 32751 United States
Neurocrine Clinical Site, Boston, Massachusetts 02116 United States
Neurocrine Clinical Site, Watertown, Massachusetts 02472 United States
Eligibility Criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1). * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. * Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.
Impact of Preterm Birth on Symptoms of Anxiety and Depression in Parents, and on the Precursors of Cognition, Including Social Cognition in Their Child
NCT05734768
Recruiting
Conditions Parental Anxiety Following Premature Bir...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

In 2018, the World Health Organization (WHO) counted no less than 15 million preterm births each year worldwide, or more than one in ten children. In recent years, the number of newborns surviving preterm birth has gradually increased due to advances in neonatal medicine. However, these rescues are not without consequences. Indeed, to do so, the child is separated from his parents, placed in a stressful, technical and potentially painful environment. This early separation is compounded by medical co-morbidities and sedations that compromise the child's physiology and availability to interact. Extreme prematurity also disrupts the early interactions between the child and his parents, and eventually the relationships with others. Thus, more than 35% of children born prematurely show insecure attachment behavior in their relationships with others. Moreover, premature births are accompanied by numerous somatic, cognitive and social cognitive difficulties. At school age, these children present more learning, social-emotional and behavioral problems. The greater the degree of prematurity, the more marked these difficulties are. They would be associated with an executive and social cognition deficit, inherent to a globally altered cerebral development, in particular the frontal subcortical cerebral regions. On the parents' side, premature birth is also fraught with consequences. Indeed, the idea of an idealized post-natal period gives way to an anxious, even traumatic experience. Notions of guilt are often expressed, as well as major anxiety about the child's survival and "parenting skills". A higher prevalence of signs of parental anxiety, postnatal depression and post-traumatic stress disorder is observed in mothers of premature infants, even up to 18 months after birth. These psychological states influence the parents' ability to interact with their newborn, as well as the content of these interactions. Finally, both parents and newborns see, for different reasons, their ability to interact and to reassure themselves profoundly disrupted by premature birth. Even if since 2010, prematurity has been identified as a "public health problem" by the WHO, studies on the subject still have limitations. Indeed, if we estimate that the prevalence of anxiety and/or depression signs in mothers of premature babies is on average three times higher than in mothers of full-term babies; what about fathers? It seems fundamental to improve our knowledge of the anxious and depressive symptoms that fathers and mothers of premature babies may display, with the aim of providing comprehensive and multidisciplinary care for families in neonatal intensive care units. Similarly, the exact impact of an increase in parental anxious depressive symptomatology on the precursors of cognitive and social cognitive development is not known. Since the environment and stimulation are fundamental to the child's development, what happens when one or both parents have their…

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Behavioral: State-Trait Anxiety Inventory - Y ou STAI-Y — Questionnaire

Primary Outcomes

  • STAI-Y : State Trait Inventory Anxiety - Y (week 7 weeks post partum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-28
Completion: 2028-05-28
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHU de Reims
Contact Information
Study Contact:
Julien EUTROPE
3 26 78 94 76
jeutrope@chu-reims.fr
Interventions
  • Behavioral: State-Trait Anxiety Inventory - Y ou STAI-Y — Questionnaire
Study Locations (1 sites)
Chu Reims, Reims, 51092 France
Eligibility Criteria
Inclusion Criteria: Children and their parents will be included in the study in the exposed group if: * the infant is born preterm, i.e., between 32 weeks of amenorrhea (SA) and 36 SA + 6 days. * at the maternity ward of the University Hospital of Reims * the parents are older than 18 years. * parents are affiliated to a social insurance. * parents agreed to participate in the study, within 72 hours after birth Will be included in the study, in the non-exposed group, children and their parents, if: * the children is born at term, i.e., from 37 SA + 0 Days * at the maternity ward of the Reims University Hospital * parents are older than 18 years. * parents are affiliated to a social insurance. * parents agreed to participate in the study, within 72 hours after birth Exclusion Criteria: Will not be included in the study, children and their parents, if: * the infant is born from multiple pregnancy * the infant is hemodynamically unstable * the birth occured more than 72 hours ago * the infant is affected by congenital malformations * the infant is affected by severe brain lesion detected by transfontanellar ultrasound scan performed before inclusion (cystic leukomalacia, and stages III and IV of the Papille classification i.e. severe ventricular dilatation or intra-parenchymal hemorrhage) * separation from the parents and placement of the child is intended * child is born anounymously * parents with psychiatric disorders * if the mother is suffering from hemodynamic compromise * parents under guardianship * parents non-native speaking
NICU Utilization of Remote Voice Technology to Improve mateRnal Experience (NURTURE)
NCT07214597
Recruiting
Conditions Postpartum Depression (PPD), Self-Effica...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The study's objective is to conduct a Phase II randomized controlled trial examining the preliminary efficacy of the VoiceLove app compared to usual care on maternal postpartum depression in mothers with infants admitted to the Neonatal Intensive Care Unit (NICU). Primary aim: Assess the effects of VoiceLove on maternal postpartum depression, measured by the Edinburgh Postnatal Depression Scale (EPDS). The estimates from this study will be used for a future definitive Phase III trial. Secondary aim: Assess feasibility, acceptability, and patterns of communication and engagement among mothers, partners, and NICU clinicians during the NICU hospitalization, measured through app usage metrics, satisfaction surveys, and qualitative interviews. Additionally, we will evaluate effects of infant length of stay.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: VoiceLove mobile phone application — Access to VoiceLove app to facilitate secure, real-time communication between family members and NICU patients.

Primary Outcomes

  • Patient Engagement with the VoiceLove App (2-weeks post randomization.)
  • Edinburgh Postnatal Depression Score (EPDS) at 2-weeks post randomization. (2-weeks post randomization.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-04
Completion: 2028-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Sarah Osmundson (PRINCIPAL_INVESTIGATOR) - Vanderbilt University Medical Center
Contact Information
Study Contact:
Makenna Woods
615-936-2938
makenna.woods.1@vumc.org
Interventions
  • Device: VoiceLove mobile phone application — Access to VoiceLove app to facilitate secure, real-time communication between family members and NICU patients.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: 1. Infant: 1. Admitted to the neonatal intensive care unit (NICU) 2. Not readmitted after discharge from the NICU 3. Expected to survive at least 2 weeks 4. Expected to be admitted to the NICU for at least 2 weeks 5. Singleton gestation 2. Mother: 1. Age ≥ 18 years old 2. English speaking 3. Mother is the biological mother of the infant admitted to the NICU 4. Postpartum day 4 or less 3. Partner (NOTE: Partner enrollment is not required) 1. Mother agrees to partner's participation 2. Designated by mother as support person with infant access Exclusion Criteria 1. Infant a. Re-admission to NICU 2. Mother 1. No access to an Android or iOS smartphone 2. Unwilling to download the VoiceLove NICU app to their personal smartphone and unwilling to accept the terms and conditions of the VoiceLove app 3. No personal email address 4. Incarcerated at time of delivery or postpartum 5. Inability to obtain informed consent i. Patient's clinician refuses enrollment of the patient ii. Patient is either mentally (acute psychosis) or physically (intubated or critically ill in the ICU) unable to provide informed consent f. Unable to approach the patient (staffing, patient unavailable) g. Mother is not the intended parent (plans adoption, is a surrogate, will not have custody of the infant) 3. Partner (NOTE: Partner enrollment is not required) 1. Age \< 18 years old 2. Not English speaking 3. Inability to obtain informed consent 4. No access to an Android or iOS smartphone that is different from the mother's smartphone 5. No access to an email address that is different from the mother's email address 6. Unwilling to download the VoiceLove NICU app to their personal smartphone and unwilling to accept the terms and conditions of the VoiceLove app
Integrating Depression Care Into HIV Services for Older People With HIV Using a Stepped Care, Task-Sharing Approach.
NCT06894680
Active, positions filled
Conditions Older Adults (50-90 Years), Depression
Phase NA
Enrollment 120
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Depression levels will be compared using PHQ-9 in the Treatment as Usual arm(TAU) VS intervention arm to see if the stepped care intervention is effective in treating depression. The main questions it aims to answer are: * Needs assessment of stepped-care integration versus usual care for treating depression in older adults living with HIV? * How effective will the stepped care task-sharing (SCT) model in reducing depressive symptoms and improving HIV treatment outcomes in older PLHIV in Nigeria? Participants who screen positive for depression PHQ-9 ≥10 will be randomized into 2 arms for treatment using a systemized ballot system: TAU arm and Intervention arm. TAU arm will receive current treatment available for depression at the HIV center. Intervention arm will receive the stepped-care intervention in stages based on their symptom severity. Follow-up assessments at (6 weeks, 3months and 6 months) will be conducted by assessors who would be blinded to the different groups (TAU arm VS intervention arm).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Stepped care — It is a systematic, staged approach to delivering care based on the severity of a condition and the patient's response to treatment. In this model, less intensive interventions are provided first, and only those who do not improve progress to more intensive treatments. In clinical research, stepped-care is classified as an adaptive intervention, where treatment is adjusted based on pre-specified criteria, making it patient-centered and resource-efficient.
  • Other: Treatment as usual — Clients that are considered to be depressed are offered counselling by the Nurses who are the first point of contact. Depending on the severity of symptoms the client are then referred to the medical officer at the HIV clinic for assessment and offered counselling services by the counsellors. if symptoms are severe and considered to need specialist care the medical officer will refer to a specialist(psychiatrist) outside the HIV care facility.

Primary Outcomes

  • Effectiveness of a Stepped-Care Task-Sharing (SCT) Model in reducing depressive symptoms measured by PHQ-9. (Baseline PHQ-9 score (before intervention) Follow-up assessments at 6 weeks, 3 months, and 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2025-03-24
Completion: 2026-03-24
Eligibility
Age: 50 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal Society of Tropical Medicine and Hygiene
Principal Investigators:
  • Olufisayo O Elugbadebo, MBBS, Msc (PRINCIPAL_INVESTIGATOR) - Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Other: Stepped care — It is a systematic, staged approach to delivering care based on the severity of a condition and the patient's response to treatment. In this model, less intensive interventions are provided first, and only those who do not improve progress to more intensive treatments. In clinical research, stepped-care is classified as an adaptive intervention, where treatment is adjusted based on pre-specified criteria, making it patient-centered and resource-efficient.
  • Other: Treatment as usual — Clients that are considered to be depressed are offered counselling by the Nurses who are the first point of contact. Depending on the severity of symptoms the client are then referred to the medical officer at the HIV clinic for assessment and offered counselling services by the counsellors. if symptoms are severe and considered to need specialist care the medical officer will refer to a specialist(psychiatrist) outside the HIV care facility.
Study Locations (1 sites)
Institute of Infectious Diseases, Ibadan, Oyo State 200212 Nigeria
Eligibility Criteria
Inclusion Criteria: * Consenting individuals living with HIV * People living with HIV who are 50 years and above (PLHIV aged ≥50 years) * Those with a score of ≥10 on the 9-item patient-health questionnaire (PHQ-9). Exclusion Criteria: * • Older PLHIV will be assessed for the imminent risk of suicide and if there is an high risk, participant will be excluded. * Older PLHIV with severe cognitive impairment or diagnosed dementia that limits their ability to provide informed consent or complete study visits will be excluded. * Participants with comorbidities that can preclude the use of sertraline should be excluded.
MISAPSY: Childhood Maltreatment, Food Insecurity, Psychological Distress and Professional Integration Among Socioeconomically Disadvantaged Young Adults
NCT07427524
Not yet recruiting
Conditions Trauma and Stress-related Disorders, Foo...
Phase NA
Enrollment 70
Locations 6 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The MISAPSY study (Childhood Maltreatment, Food Insecurity, Psychological Distress and Professional Integration Among Socioeconomically Disadvantaged Young Adults) aims to model the complex interrelations between child maltreatment, trauma exposure, food insecurity, and psychological distress among precarious young adults enrolled in French youth employment and social integration services (Mission Locale). Adopting a methodology structured around three complementary components, this study consists of: (1) a cross-sectional survey to identify key associations ; (2) a qualitative study based on semi-structured interviews exploring psychologists' subjective experiences, and (3) a longitudinal comparative interventional study involving two different support programs to assess and compare the impact of these interventions on participants' food insecurity and psychological well-being. Using a multi-phase design, MISAPSY seeks to move beyond linear risk-factor models by adopting a systemic and network-based approach to mental health and social vulnerability. The study integrates quantitative analyses, including network analyses, qualitative exploration of professional practices, and comparative longitudinal intervention to inform more holistic, equitable, and transferable models of care for vulnerable young adults.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Food Assistance — Weekly food assistance provided to participants for a duration of 12 months, aimed at reducing food insecurity.
  • Behavioral: Psychological Follow-Up — Twice-monthly psychological follow-up sessions provided over a 6-month period, delivered by trained psychodynamic psychologists, aiming to support psychological well-being and address trauma-related psychological distress.

Primary Outcomes

  • Change in Food Insecurity Severity (T0: Baseline; T1: 3 months after baseline; T2: 6 months after baseline (end of the psychological follow-up); and T3: 12 months after baseline (end of the study))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-07-01
Completion: 2027-06
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Lorraine
Principal Investigators:
  • Aziz Essadek, PhD (PRINCIPAL_INVESTIGATOR) - Université de Paris Cité
Contact Information
Study Contact:
Aziz ESSADEK, PhD
+33667344173
aziz.essadek@u-paris.fr
Maud Cappelletti, PhD student
maud.cappelletti@univ-lorraine.fr
Interventions
  • Other: Food Assistance — Weekly food assistance provided to participants for a duration of 12 months, aimed at reducing food insecurity.
  • Behavioral: Psychological Follow-Up — Twice-monthly psychological follow-up sessions provided over a 6-month period, delivered by trained psychodynamic psychologists, aiming to support psychological well-being and address trauma-related psychological distress.
Study Locations (6 sites)
Mission Locale site Centre, Paris, 75011 France
Mission Locale site Soleil, Paris, 75013 France
Mission Locale site Avenir, Paris, 75014 France
Mission Locale site Milord, Paris, 75018 France
Mission Locale site Est, Paris, 75019 France
Mission Locale site Pyrénées, Paris, 75020 France
Eligibility Criteria
Inclusion Criteria: * Be aged 18 to 25 years * Be supported by a Mission Locale in Paris as part of a social and/or professional integration program * Voluntarily participate in the study after receiving clear information and signing an informed consent form * Experiencing severe food insecurity (positive response to item 8 of the FIES) * Experiencing significant psychological distress, defined by: PHQ-9 score \> 15; GAD-7 score \> 10 * Have been exposed to at least one adverse childhood experience, identified via the CTQ-SF (Childhood Trauma Questionnaire - Short Form). Exclusion Criteria: * Being unable to provide informed consent due to impaired comprehension or communication skills * Currently receiving psychiatric care for an acute or chronic mental illness requiring regular specialized treatment * Experiencing a social or medical emergency incompatible with the study (e.g., unstable emergency housing, acute suicidal crisis, ongoing hospitalization) * Being incarcerated, under guardianship or curatorship without specific legal authorization to participate in research * Having previously participated in a similar study or currently being engaged in a structured psychological intervention protocol * Having insufficient command of the French language, preventing comprehension of instructions, questionnaires, or interviews.
Clinical Effectiveness of TARA Compared to Standard Treatment for Adolescents and Young Adults With Depression
NCT04747340
Active, positions filled
Conditions Depression in Adolescence, Depressive Di...
Phase NA
Enrollment 136
Locations 3 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Depressive Disorders constitute an increasing global health concern and available treatments for young people have not been sufficiently effective in haltering this trend. The novel group treatment program "Training for Awareness, Resilience, and Action" (TARA) was developed to target specific mechanisms based on neuroscientific findings in adolescent depression. TARA is framed within the National Institute of Mental Health's Research Domain Criteria and has documented feasibility and preliminary efficacy in adolescents with depression. In this study, young people (age: 15-22) with depression will be recruited from specialized Child and Adolescent Psychiatry and Youth Clinics and randomized to receive either TARA or Standard Treatment (ST) until n=67 is reached in each arm. Outcome measures will be obtained before randomization (T0), 6 weeks after treatment start (T0.5), at 3- and 6 months follow-up (T1, T2). The primary outcome measure is Reynold's Adolescent Depression Scale (RADS-2) score at T1. Secondary outcome measures are RADS-2-score at T2, clinician depression rating with Children's Depression Rating Scale, Revised at T1,and self-rated anxiety with Multidimensional Anxiety Scale for Children, 2nd ed. at T1 and T2. Other outcomes include heart rate variability and systemic bioindicators for depression from blood and hair. Data collected from subgroups within the study will include: brain magnetic resonance imaging and accelerometry. Qualitative interviews will be performed to reach a more comprehensive understanding of the subjective experience of being depressed and to what extent treatment adequately addresses this experience. A 2-year follow-up (T3) will be performed and presented separately. The study will be the first Randomized Controlled Trial to examine the clinical effectiveness of TARA compared to ST for young people with depression. The investigators hypothesize that (1) TARA will result in greater reduction of depression symptoms compared to ST and that group differences will be maintained or increased at T2, (2) the treatment effect of TARA will be mediated by improved emotion regulation, sleep, and psychological flexibility, (3) bioindicators for depression will improve more in the TARA-arm compared to the ST-arm, (4) it will be possible/meaningful to explore the contextual factors perceived to drive the depression onset and maintenance, and the extent to which the different treatments address these factors.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Training for Awareness Resilience and Action (TARA) — See arm-description
  • Other: Standard treatment — See arm-description

Primary Outcomes

  • Reynold's Adolescent Depression Scale 2nd edition (3 month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2021-03-12
Completion: 2029-01-01
Eligibility
Age: 15 Years
Sex: ALL
Volunteers: false
Enrollment: 136 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Umeå University
Collaborators: Västerbotten County Council, Sweden, Västernorrland County Council, Sweden
Principal Investigators:
  • Eva Henje, MD, PhD (PRINCIPAL_INVESTIGATOR) - Umeå Universitet
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: Training for Awareness Resilience and Action (TARA) — See arm-description
  • Other: Standard treatment — See arm-description
Study Locations (3 sites)
Ungdomshälsan/primary care, Umeå and Skellefteå, Västerbotten County 90328 Sweden
Barn och Ungdomspsykiatriska kliniken, Umeå, Skellefteå, and Lycksele, Västerbotten County 90364 Sweden
Barn och Ungdomspsykiatriska kliniken, Örnsköldsvik and Sundsvall, Västernorrland County 89135 Sweden
Eligibility Criteria
Inclusion Criteria: * Outpatient at the CAP or YC unit * The criteria for a diagnosis Major Depressive Disorder (MDD) or Persistent Depressive disorder (PDD)/dysthymia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV or 5 are fulfilled. The clinical diagnosis will be validated during the screening process using the Mini International Neuropsychiatric Interview (M.I.N.I.)/Mini-International Neuropsychiatric Interview for Children and Adolescents (M.I.N.I-kid). If a diagnosis of MDD or PDD/dysthymia is not conclusive a cut-off of 40 or above on the Children's' Depression Rating Scale - Revised will be used for inclusion. * For patients in specialist child- and adolescent psychiatry clinics below the age of 18 one parent/ legal guardian must be available and agree to participate in parts of the sessions in case the individual is randomized to the TARA-arm. Exclusion Criteria: 1. One or several severe psychiatric co-morbid diagnoses that may interfere with or hinder group participation, including: intellectual development disorder, severe autism spectrum disorder, psychotic disorder, bipolar disorder, severe anorexia nervosa, substance use disorders, acute posttraumatic stress disorder (PTSD) and severe dissociative syndromes. 2. One or several psychiatric symptoms or behavioral problems that may interfere with or hinder group participation including: * Severe self-harming behavior * Acute suicidality, including a reported suicide attempt in the last 6 months or hospitalization for suicidality in the last 6 months * Disabling dissociative symptoms or \> 6 points as mean item score on the Adolescent Dissociative Experiencing Scale. * Frequent use of recreational drugs (a urine drug screen will be performed at baseline and if positive a second test has to be negative for inclusion) * Reports of manic or hypomanic symptoms during the last year 3. A first degree relative with bipolar disorder (a first episode of MDD may be an incipient bipolar disorder which is not the treatment target for TARA). 4. On-going trauma, neglect, abuse or domestic violence or destabilizing legal process. 5. Pregnancy 6. Non-fluency in oral and written Swedish since the TARA groups are held in Swedish and assessment forms are in Swedish Note: Other psychiatric comorbidities such as attention deficit hyperactivity disorder (ADHD), anxiety, high functioning autism spectrum disorder and mild to moderate eating disorders are not considered exclusion criteria. Accidental findings of biochemical anomalies will not be considered exclusion criteria and medical conditions will be referred for appropriate treatment.